Follow-up and prognosis of HCM

Domínguez, Fernándo; Sanz‐Sánchez, Jorge; García‐Pavía, Pablo; Zorio, Esther

doi:10.21542/gcsp.2018.33

Cited by 4 publications

(4 citation statements)

References 73 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Improve diastolic filling, reduced outflow gradient, improve perfusion to the subendocardium 5 Disopyramide Class Ia antiarrhythmic drug, decreases permeability of Na + channels during phase 0; decreases myocardial excitability and conduction velocity 30 Useful adjunct to β-blockers and calcium channel blockers 2 Increases morbidity and mortality in atrial fibrillation and HCM 31 Increases risk of QTc prolongation and anticholinergic adverse effects 5,30 Diuretics Depletes volume and decreases stroke volume, worsens LVOT gradient 1 For patients with diastolic dysfunction and who require relatively high filling pressure to achieve adequate ventricular filling 1…”

Section: Experimental Therapiesmentioning

confidence: 99%

A Narrative Review of the Pathophysiology and Treatment of Hypertrophic Cardiomyopathy

Acevedo

Salinas

Polanco

et al. 2022

Southern Medical Journal

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is a genetic autosomal dominant disorder of the heart muscle that is characterized by left ventricular hypertrophy and sudden cardiac death. It is the most common inherited cardiac disease. HCM is defined by sarcomeric mutations that result in fibrosis of the heart, affecting contraction. In most cases, clinical presentations can range from asymptomatic to systolic and diastolic ventricular dysfunction, arrhythmias, and sudden cardiac death. Some histopathologic features typical of the disease are changes in myocyte disarray and myocardial fibrosis. Mutations in the β-myosin heavy chain and myosin-binding protein C have been identified as the cause of the disease. The goals of pharmacological therapy as well as nonpharmacological therapy are to alleviate the symptoms and to prevent sudden cardiac death. Anatomical defects are treated primarily by surgical intervention, whereas other issues such as hypercontractility are treated with pharmacotherapy. In this article, we review the pathophysiology and treatment options for HCM.

show abstract

Section: Experimental Therapiesmentioning

confidence: 99%

A Narrative Review of the Pathophysiology and Treatment of Hypertrophic Cardiomyopathy

Acevedo

Salinas

Polanco

et al. 2022

Southern Medical Journal

View full text Add to dashboard Cite

show abstract

“…Patients should see their dentist every 6 months to reduce the possibility of dental or oral infections that can lead to endocarditis 29. Patients also should follow up with their primary care provider or cardiologist every 6 to 12 months depending on disease severity 30. Keeping BP below 130/80 mm Hg can help patients reduce the risk of developing LV hypertrophy secondary to increased afterload 31.…”

Section: Treatmentmentioning

confidence: 99%

“…29 Patients also should follow up with their primary care provider or cardiologist every 6 to 12 months depending on disease severity. 30 Keeping BP below 130/80 mm Hg can help patients reduce the risk of developing LV hypertrophy secondary to increased afterload. 31 Lastly, educate patients on avoiding smoking and illicit drugs.…”

Section: Treatmentmentioning

confidence: 99%

Screening for hypertrophic cardiomyopathy

Pydah

Mauck²,

Shultis³

et al. 2021

Jaapa

View full text Add to dashboard Cite

Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and causes changes in the cardiac muscle affecting ventricular, valvular, and cellular functions. Because HCM is an inherited disorder, all age groups are affected; however, it commonly presents in adolescents, especially athletes. Many patients are asymptomatic and undiagnosed, putting them at risk for sudden cardiac death. This article describes screening and management of patients with HCM.

show abstract

“…Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary cardiovascular diseases [ 1 – 4 ] characterized by asymmetrical myocardial hypertrophy, cardiomyocyte disarray, and interstitial fibrosis [ 5 ]. These pathophysiologic abnormalities lead to increased risks of outflow tract obstruction, heart failure, arrhythmia, stroke, and death [ 6 ]. Compared with the general population, patients with HCM are at a significantly higher risk of developing AF, which might be attributed to atrial cardiomyopathy and atrial enlargement due to left ventricular diastolic dysfunction [ 7 – 10 ].…”

Section: Introductionmentioning

confidence: 99%

The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation

Lyu,

Zhu,

Wang

et al. 2024

Thrombosis J

View full text Add to dashboard Cite

Background The benefit-risk profile of direct oral anticoagulants (DOAC) therapy in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF) has not been well established yet. This study aimed to evaluate the efficacy and safety of DOAC compared with vitamin K antagonists (VKA) in patients with HCM and AF. Methods PubMed, EMBASE, the Cochrane Library, and clinicaltrials.gov were searched to identify studies comparing DOAC with VKA in patients with HCM and AF. The primary endpoint was thromboembolic events. The relative risks and standard errors were pooled by random-effect models using the generic inverse variance method. Results Seven observational studies involving 9395 patients were included in this meta-analysis. Compared to the VKA group, the DOAC group displayed a similar risk of thromboembolic events [RR (95%CI): 0.93 (0.73–1.20), p = 0.59] and ischemic stroke [RR (95%CI): 0.65 (0.33–1.28), p = 0.22]. The incidence of major bleeding was comparable between the two groups [RR (95%CI): 0.75 (0.49–1.15), p = 0.19]. Meanwhile, DOAC therapy was superior to VKA therapy in reducing the incidences of all-cause death [RR (95%CI): 0.44 (0.35–0.55), p < 0.001], cardiovascular death [RR (95%CI): 0.41 (0.22–0.75), p = 0.004], and intracranial hemorrhage [RR (95%CI): 0.42 (0.24–0.74), p = 0.003]. Conclusion In patients with HCM and AF, DOAC therapy was similar to VKA therapy in reducing the risk of thromboembolic events, without increasing bleeding risk. In addition, the DOAC group displayed significant advantages in reducing mortality and intracranial hemorrhage compared with the VKA group. Further randomized controlled trials are needed to provide more evidence for DOAC therapy in this population.

show abstract

Follow-up and prognosis of HCM

Cited by 4 publications

References 73 publications

A Narrative Review of the Pathophysiology and Treatment of Hypertrophic Cardiomyopathy

A Narrative Review of the Pathophysiology and Treatment of Hypertrophic Cardiomyopathy

Screening for hypertrophic cardiomyopathy

The efficacy and safety of direct oral anticoagulants compared with vitamin K antagonist in patients with hypertrophic cardiomyopathy and atrial fibrillation

Contact Info

Product

Resources

About